The Strōma Laser System is designed to reveal underlying natural eye colors.
Darker eyes are mysterious and beautiful, and just underneath the darker surface pigment lie unique shades of amber, hazel, grey, green, and blue.
Procedure






Pigment
In dark eyes, the iris surface is covered by a thin layer of brown pigment.

Change
During an in-office procedure, a Strōma-certified physician will use the patented Strōma Laser System to deliver energy several times to this thin layer of iris pigment. This procedure takes less than one minute per eye. The number of treatments required depends upon how dark the eye is before treatment and the desired eye color the patient hopes to achieve.

Reveal
In three to four weeks after the procedure, the natural underlying eye color should gradually be revealed.


Strōma is the leader in permanent eye color change, with its revolutionary Strōma® Laser System.
Strōma Medical Corporation is a clinical stage medical device company located in Irvine, California. Strōma has developed the Strōma Laser System, a patented laser technology to change eye color from brown, hazel or black to a natural-looking amber, hazel, grey/blue, blue, or green eye. This surgically non-invasive treatment requires only a topical anesthetic, is performed in a doctor’s office, requires minimal recovery time, and can be performed in less than a minute per eye per treatment.
The Strōma Laser System is a stand-alone technology intended to be leased to refractive surgeons worldwide (e.g., LASIK-certified ophthalmologists). Ophthalmologists with an established laser practice generally have the infrastructure necessary to market, recruit, educate, and follow-up with patients.
Strōma is well positioned to capitalize on the large unmet demand for permanent eye-color change by providing consumers with a simple solution designed for a safe and natural-looking result. Strōma Medical Corporation has commissioned two market research studies. The first was a primary market research study through a U.S. research firm. The study concluded that 17.5% of consumers with dark eyes would undergo the procedure if it were safe and effective, and an additional 35% would consider the procedure under the same conditions. Combined with demographic research findings, Strōma predicts a U.S. market of approximately 850,000 individuals annually. The second market research study was conducted in the E.U., Middle East, and Asia. The studies concluded that, on average, 51.8% of dark-eyed consumers between 18 and 64 would be interested in having the SLS procedure.